Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of BMS-986168 in progressive supranuclear palsy
jRCT2080223571Phase 2
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing BMS-986168 IV with Placebo IV (2 arms).
02
Drugs
gosuranemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on jRCT2080223571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223571.